<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126057</url>
  </required_header>
  <id_info>
    <org_study_id>CPRO-1908-001</org_study_id>
    <nct_id>NCT04126057</nct_id>
  </id_info>
  <brief_title>Myopia Assessment of Two Manufacturing Processes</brief_title>
  <acronym>MAPLE</acronym>
  <official_title>Myopia Assessment of Two Manufacturing Processes for Myopia Management Lenses (MAPLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SightGlass Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SightGlass Vision, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, controlled, multisite, subject- and observer-masked, contralateral clinical trial
      of 6-month duration to compare two SightGlass Vision Diffusion Optics Technology (DOT)
      spectacle lens manufacturing processes in reducing the progression of juvenile myopia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in axial length progression from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Change in axial length progression over time between DOT spectacle lenses manufactured by method A versus method B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in spherical equivalent refraction from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in spherical equivalent refraction (SER) as measured by cycloplegic autorefraction over the duration of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Juvenile Myopia</condition>
  <arm_group>
    <arm_group_label>DOT Spectacle Lenses using Manufacturing Method A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOT Spectacle Lenses using Manufacturing Method B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SightGlass Vision DOT Spectacle Lenses</intervention_name>
    <description>Subjects randomized to test vs control, left eyes and right eyes</description>
    <arm_group_label>DOT Spectacle Lenses using Manufacturing Method A</arm_group_label>
    <arm_group_label>DOT Spectacle Lenses using Manufacturing Method B</arm_group_label>
    <other_name>SightGlass Vision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between the ages of 6 and 14 years old (inclusive) with myopia

          -  Best corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen
             equivalent) or better in each eye

          -  Difference in spherical equivalent power between the two eyes (anisometropia based on
             manifest refraction) must be less than or equal to 0.75 D

        Exclusion Criteria:

          -  Current use of any myopia control treatment such as atropine, multifocal contact
             lenses, or orthokeratology (NOTE: Prior bilateral usage acceptable as long as
             treatment stopped at least 6 months before screening visit. Any subject with a history
             of unilateral myopia control treatment is excluded.)

          -  Any ocular or systemic conditions that could influence refractive development or
             status [e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan
             syndrome or other connective tissue disorder, Down's syndrome, family history of poor
             night vision (to prevent against enrolling subjects with congenital stationary night
             blindness)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Rappon, OD, MS, FAAO</last_name>
    <role>Study Chair</role>
    <affiliation>SightGlass Vision, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sabal Eye Care</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kannarr Eye Care</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Eyecare PC</name>
      <address>
        <city>Raytown</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY School of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William J Bogus, OD, FAAO</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

